In particular, the use of the monoclonal Her2-antibodies trastuzumab and/or pertuzumab in combination with docetaxel has significantly improved outcomes in patients with Her2-positive breast cancer [227,228]. The gene discussed is ERBB2; the disease is breast carcinoma.